ABCL Total Assets
Everything the company owns at each quarter end — the balance-sheet total, not a flow.
Total Assets
Latest: $1.31B (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | $1.50B |
| 2023Q2 | $1.54B |
| 2023Q3 | $1.51B |
| 2023Q4 | $1.49B |
| 2024Q1 | $1.46B |
| 2024Q2 | $1.41B |
| 2024Q3 | $1.39B |
| 2024Q4 | $1.36B |
| 2025Q1 | $1.34B |
| 2025Q2 | $1.40B |
| 2025Q3 | $1.36B |
| 2025Q4 | $1.36B |
| 2026Q1 | $1.31B |
| 2026Q2 | $1.31B |
Other Indicators
Other ABCL Charts
More quarter-by-quarter fundamentals for AbCellera Biologics Inc.
1 / 6
Revenue
EPS
Free Cash Flow
FCF Margin
Cumulative FCF
Shares Outstanding
Healthcare Comparison
1 / 3
Total Assets
Total Assets
Total Assets
Latest Total Assets: $1.31B (2026Q2); -6.7% YoY; -4.1% CAGR (3.25y).
Across the 14 quarters from 2023Q1 to 2026Q2, Total Assets ranged from $1.31B in 2026Q1 to $1.54B in 2023Q2.